U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

Impact · against what's priced in

The FDA approval of a subcutaneous induction regimen for SKYRIZI in Crohn's disease is a positive catalyst that supports the long-term growth targets the market currently demands. While the price already expects SKYRIZI to replace Humira revenue, the shift to a self-administered induction regimen increases the drug's competitive advantage in the first-line biologic market.

ABBV+0.30: Challenges what's priced in
The price assumes

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

What matters in this story

2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

What matters in this story

2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)

How each ticker is affected

Track these names every morning.

GH Research Remains Undervalued Ahead Of Pivotal Phase III Program

Telix Pharmaceuticals: The ITM Deal Could Strengthen The Long-Term Buy Case

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

Moderna leaked data was positive, what's hurting MRNA stock then?

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

What matters in this story

Next reads from the same story arc

2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

What matters in this story

Next reads from the same story arc

2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)

How each ticker is affected

Track these names every morning.

GH Research Remains Undervalued Ahead Of Pivotal Phase III Program

Telix Pharmaceuticals: The ITM Deal Could Strengthen The Long-Term Buy Case

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

Moderna leaked data was positive, what's hurting MRNA stock then?